Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 13/20 | 0.62 |
| ▸ | ACKR3 | P25106 | 4/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17840128 | 0.92 | CHRM3 (0.59) | CHRM3ACKR3CHRNB4CHRNA3KDM4E | |
| SCHEMBL17840002 | 0.90 | CHRM3 (0.59) | CHRM3ACKR3KDM4EPOLBNPBWR1 | |
| SCHEMBL17797018 | 0.86 | CHRM3 (0.54) | CHRM3 | |
| SCHEMBL17840200 | 0.86 | CHRM3 (0.60) | CHRM3 | |
| SCHEMBL17840110 | 0.83 | ACKR3 (0.49) | CHRM3ACKR3CHRNB4CHRNA3KDM4E | |
| SCHEMBL17840201 | 0.83 | CHRM3 (0.52) | CHRM3ACKR3 | |
| SCHEMBL17840050 | 0.83 | CHRM3 (0.52) | CHRM3ACKR3CHRNB4CHRNA3 | |
| SCHEMBL17840186 | 0.83 | CHRM3 (0.55) | CHRM3ACKR3CHRNB4CHRNA3 | |
| SCHEMBL17840185 | 0.83 | CHRM3 (0.55) | CHRM3ACKR3CHRNB4CHRNA3 | |
| SCHEMBL17840229 | 0.82 | CHRM3 (0.61) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828339-B2 | Biphenyl derivatives and methods for preparing same | DONG-A ST CO., LTD (KR) | 2017-11-28 | — | — | US | disclosed |
| US-20160176816-A1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | DONG-A ST CO., LTD (KR) | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176816-A1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | CHRM2, CHRM3, CHRM5 | CHRM3 2/4885ACKR3 978/4885CHRNB4 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.